Federated Hermes Inc. Purchases 96,543 Shares of Humana Inc. $HUM

Federated Hermes Inc. grew its position in Humana Inc. (NYSE:HUM) by 68.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 237,499 shares of the insurance provider’s stock after purchasing an additional 96,543 shares during the period. Federated Hermes Inc.’s holdings in Humana were worth $61,790,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. Elevation Point Wealth Partners LLC bought a new position in shares of Humana during the 2nd quarter worth approximately $32,000. Mather Group LLC. purchased a new stake in shares of Humana during the third quarter valued at approximately $34,000. AlphaCore Capital LLC bought a new stake in Humana during the second quarter worth $39,000. Private Wealth Management Group LLC boosted its position in Humana by 47.5% in the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Finally, SJS Investment Consulting Inc. grew its stake in Humana by 19,300.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock valued at $50,000 after purchasing an additional 193 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Analysts calling Humana oversold — Some commentators flag HUM as a top oversold S&P 500 stock with significant upside if fundamentals stabilize, suggesting a potential buying opportunity for value investors. These Are the 3 Top Oversold S&P 500 Stocks
• Positive Sentiment: “Time to buy?” thesis — Some retail/contrarian pieces argue the sharp decline could create a long‑term entry point given Humana’s Medicare Advantage footprint and prior earnings power, but they note increased near‑term policy risk. Humana’s Health Scare Sinks Stock To 9-Year Low. Time To Buy?
• Neutral Sentiment: Industry rout context — Coverage highlights that UnitedHealth and other insurers also sold off after the CMS proposal, underscoring this is a sector move driven by policy, not company‑specific operational news. UnitedHealth Leads $80 Billion Insurer Rout
• Neutral Sentiment: Valuation questions raised — Commentaries are debating whether the lower price creates value or a “value trap,” signaling investor uncertainty about Humana’s ability to offset tighter CMS rates with efficiency or growth. Is Humana Stock Now A Value Trap At $200?
• Negative Sentiment: CMS Medicare Advantage payment update triggered the crash — An advanced notice proposing flat/tighter MA funding for 2027 directly pressures Humana’s Medicare Advantage margins and prompted the ~21% drop as investors cut forward earnings expectations. Humana (HUM) Falls 21% on Medicare Payment Update
• Negative Sentiment: Shares hit multi‑year/52‑week lows and heavy selling — Coverage documents the sharp decline to the lowest levels since 2017 and flag heightened downside risk if CMS final rates stay weak or if insurers lower guidance. Humana stock hits 52-week low
• Negative Sentiment: Local/provider relationships and margin pressures — Reports note potential disruptions (e.g., provider partners reassessing ties) and expansion of cost‑intensive services (at‑home care) that may compress near‑term margins under tighter CMS funding. Queen’s May Cut Ties With This For‑Profit Medicare Insurer

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HUM shares. The Goldman Sachs Group lowered their target price on Humana from $235.00 to $215.00 and set a “sell” rating on the stock in a research note on Monday, November 24th. Sanford C. Bernstein restated an “outperform” rating and set a $344.00 price objective on shares of Humana in a report on Tuesday, January 6th. Bank of America lifted their price objective on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a research report on Friday, October 10th. Barclays reissued an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Finally, Morgan Stanley restated an “underperform” rating on shares of Humana in a research note on Thursday, December 18th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, Humana presently has an average rating of “Hold” and an average price target of $293.37.

Humana Price Performance

Shares of NYSE:HUM opened at $196.48 on Friday. The firm has a market capitalization of $23.63 billion, a PE ratio of 18.41, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $257.08 and a two-hundred day moving average price of $263.95. Humana Inc. has a twelve month low of $191.39 and a twelve month high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.16 earnings per share. Equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.